Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Dove Medical Press full text link Dove Medical Press Free PMC article
Full text links

Actions

Observational Study
.2020 Nov 26:16:489-495.
doi: 10.2147/VHRM.S236286. eCollection 2020.

Platelet-Derived Microparticles (MPs) and Thrombin Generation Velocity in Deep Vein Thrombosis (DVT): Results of a Case-Control Study

Affiliations
Observational Study

Platelet-Derived Microparticles (MPs) and Thrombin Generation Velocity in Deep Vein Thrombosis (DVT): Results of a Case-Control Study

Salvatore Santo Signorelli et al. Vasc Health Risk Manag..

Abstract

Introduction: The role of platelets (Ps) and platelet-derived microparticles (MPs) in venous thromboembolism (VTE) is still being debated.

Methods: We measured MPs, velocity of thrombin formation (PiCT) and phospholipid generation (PLPs) in 40 patients with unprovoked deep vein thrombosis (DVT), who were compared with 40 healthy controls.

Results: MPs were higher in DVT (7.12 nM; 25th-75th percentile 5.26-9.12) than in controls (5.45 nM; 25th-75th percentile 1.67-8.96) (p = 0.19). PiCT velocity was lower in DVT (1.87 sec; 25th-75th percentile 1.75-1.93 sec) compared with controls (1.95 sec; 25th-75th percentile 1.84-2.24 sec) (p = 0.04). PLPs were higher in DVT (77.03 µg/mL; 25th-75th percentile 72.12-103.59 µg/mL) compared with controls (68.65 µg/mL, 25th-75th percentile 55.31-78.20 µg/mL) (p = 0.02).

Discussion: We hypothesize that MPs could be integrated with the lab network assay in evaluating Ps' role as an activated procoagulative condition. We encourage research on Ps and P-derived microvesicle pathways in patients with unprovoked DVT and not only in patients with cancer-induced DVT.

Keywords: biomarkers; deep vein thrombosis; extracellular vesicles; microparticles; platelet.

© 2020 Signorelli et al.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Box-plot showing the distribution of microparticle (MP) quantification by controls and DVT cases.
Figure 2
Figure 2
Box-plot showing the distribution of prothrombinase-induced clotting time assay (PiCT) velocity by controls and DVT cases. The asterisks are outliers, and the dots are extreme values. The numbers identify the sample to which the asterisk or dot refers.
Figure 3
Figure 3
Box-plot showing the distribution of phospholipid (PLP) quantification by controls and DVT cases.
See this image and copyright information in PMC

References

    1. Writing Group M, Mozaffarian D, Benjamin EJ, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association.Circulation. 2016;133:e38–e360. - PubMed
    1. Mahajan A, Brunson A, White R, et al. The epidemiology of cancer-associated venous thromboembolism: an update.Semin Thromb Hemost. 2019;45(4):321–325. doi: 10.1055/s-0039-1688494 - DOI - PubMed
    1. Jara-Palomares L, van Es N, Praena-Fernandez JM, et al. Relationship between type of unprovoked venous thromboembolism and cancer location: an individual patient data meta-analysis.Thromb Res. 2019;176:79–84. doi: 10.1016/j.thromres.2019.02.011 - DOI - PubMed
    1. Figueroa A, Alfonso A, Lopez-Picazo J, et al. Insights into venous thromboembolism prevention in hospitalized cancer patients: lessons from a prospective study.PLoS One. 2018;13(8):e0200220. doi: 10.1371/journal.pone.0200220 - DOI - PMC - PubMed
    1. Di Nisio M, Candeloro M, Rutjes AWS, et al. Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis.J Thromb Haemost. 2018;16(7):1336–1346. doi: 10.1111/jth.14149 - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

Full text links
Dove Medical Press full text link Dove Medical Press Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2026 Movatter.jp